Country: Canada
Language: English
Source: Health Canada
ALFACALCIDOL
CHEPLAPHARM ARZNEIMITTEL GMBH
A11CC03
ALFACALCIDOL
2MCG
DROPS
ALFACALCIDOL 2MCG
ORAL
15G/50G
Prescription
VITAMIN D
Active ingredient group (AIG) number: 0135700005; AHFS:
APPROVED
1999-06-16
_ONE-ALPHA® (alfacalcidol) Product Monograph _ _Page 1 of 32_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR ONE-ALPHA® Alfacalcidol Capsules, 0.25 and 1 mcg, oral Oral Drops, 2 mcg/mL, oral Injection, 2 mcg/mL, intravenous Vitamin D Analogue A11CC03 VITAMIN D AND ANALOGUES CHEPLAPHARM Arzneimittel GmbH Ziegelhof 24 17489 Greifswald Germany www.cheplapharm.com Importer / Distributor: Xediton Pharmaceuticals Inc. 2000 Argentia Rd Mississauga Ontario L5N 1W1 Date of Initial Authorization: December 31, 1980 (Capsules, 0.25 and 1 mcg) December 04, 2000 (Oral Drops, 2 mcg/mL) February 20, 2001 (Injection, 2 mcg/mL) Date of Revision: 26 January 2022 Submission Control Number: 251287 ®Registered trademark of CHEPLAPHARM Arzneimittel GmbH used under license by Xediton Pharmaceuticals Inc., Mississauga, Ontario L5N 1W1 _ONE-ALPHA® (alfacalcidol) Product Monograph _ _Page 2 of 32 _ TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. 1. INDICATIONS ................................................................................................................ 4 1.1. Pediatrics ............................................................................................................ 4 1.2. Geriatrics ............................................................................................................ 4 2. CONTRAINDICATIONS ................................................................................................. 4 4. DOSAGE AND ADMINISTRATION ............................................................................... 4 4.1. Dosing Considerations ........................................................................................ 4 4.2. Recommended Dose and Dosage Adjustment .................................................... 7 4.3. Reconstitution ..................................................................................................... 8 4.4. Administration ........................................................ Read the complete document